NASDAQ:OKYO

OKYO Pharma (OKYO) Stock Price, News & Analysis

OKYO Pharma logo
$1.18 -0.18 (-12.96%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.18 0.00 (0.00%)
As of 11/16/2026 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About OKYO Pharma Stock (NASDAQ:OKYO)

Advanced

Key Stats

Today's Range
$1.15
▼
$1.35
50-Day Range
$1.18
▼
$1.54
52-Week Range
$1.15
▼
$3.20
Volume
3.71 million shs
Average Volume
68,455 shs
Market Capitalization
$61.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67
Consensus Rating
Moderate Buy

Company Overview

OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and ocular pain. Its research focuses on therapies intended to reduce inflammation and improve symptoms affecting the eye.

The company’s lead candidate, urcosimod (OK-101), is a topical eye-drop treatment being developed for dry eye disease. It is designed to act on ChemR23, a receptor involved in regulating inflammation. OKYO has also investigated the candidate’s potential for treating neuropathic corneal pain.

AI Generated. May Contain Errors.

OKYO Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

OKYO MarketRank™: 
3.04362326574 of 5 stars

OKYO Pharma scored higher than 61% of companies evaluated by MarketBeat, and ranked 349th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OKYO Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    OKYO Pharma has a consensus price target of $5.67, representing about 382.3% upside from its current price of $1.18.

  • Amount of Analyst Coverage

    OKYO Pharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about OKYO Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for OKYO Pharma are expected to decrease in the coming year, from ($0.13) to ($0.15) per share.

  • Price to Book Value per Share Ratio

    OKYO Pharma has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about OKYO Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.15% of the float of OKYO Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    OKYO Pharma has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in OKYO Pharma has recently decreased by 40.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    OKYO Pharma does not currently pay a dividend.

  • Dividend Growth

    OKYO Pharma does not have a long track record of dividend growth.

  • News Sentiment

    OKYO Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for OKYO Pharma this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    2.97% of the stock of OKYO Pharma is held by institutions.

  • Read more about OKYO Pharma's insider trading history.
Receive OKYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OKYO Stock News Headlines

Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
See More Headlines

OKYO Stock Analysis - Frequently Asked Questions

OKYO Pharma's stock was trading at $2.07 at the beginning of the year. Since then, OKYO shares have decreased by 43.2% and is now trading at $1.1750.

OKYO Pharma (OKYO) raised $2 million in an IPO on Tuesday, May 17th 2022. The company issued 625,000 shares at $4.00 per share.

Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Energy Transfer (ET), Pfizer (PFE), Denison Mine (DNN), Aurora Cannabis (ACB), Atlas Lithium (ATLX), Bitfarms (BITF) and Celsius (CELH).

Company Calendar

Today
11/17/2026
Next Earnings (Estimated)
12/02/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:OKYO
CIK
1849296
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$5.00
Potential Upside/Downside
+382.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.43
Quick Ratio
2.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.30 per share
Price / Book
3.92

Miscellaneous

Outstanding Shares
52,480,000
Free Float
31,247,000
Market Cap
$61.66 million
Optionable
Not Optionable
Beta
0.02
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:OKYO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners